Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises EQT on merger of FocusVision and Confirmit
Mandate

Vinge advises EQT on merger of FocusVision and Confirmit

January 08, 2021 Employment and Benefits Banking and Finance EU, Competition and Regulatory M&A

The Nordic-based PE-forms EQT and Verdance intends to merger their respective portfolio companies FocusVision and Confirmit.

FocusVision was acuiered by EQT 201t and provides software and services for market research. Confirmit was acquired by Verdane 2019 and provides solutions for, inter alia, customer experience and market research. The merger is subject to customary regulatory approvals. 

Vinge’s team consisted of partners Christina Kokko (M&A), Marcus Glader (EU & Competition) and Albert Wållgren (Banking & Finance) and associates Stina Bengtsson (M&A), Pauline Lagerstrand, (Banking & Finance), Ebba Svenburg (Employment), Emma Johansson, Sebastian Örndahl, Anna Grigorian, Xandra Ståhlberg and Alice Noguier (EU & Competition).

Related

Vinge advised Precise Biometrics

 Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

 Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026